Approach: Engineered and targeted cytokines to treat autoimmune diseases
Strategic Area: Immunotherapies
T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug
Strategic Area: Immunotherapies
T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug
Location: France, Ile-de-France, Paris
Investors 5
| Date | Name | Website |
| 06.02.2022 | Takeda Ven... | takeda.com |
| 02.08.2022 | T1D Fund | t1dfund.or... |
| - | Fund+ | fundplus.b... |
| - | Bioqube Ve... | bioqubeven... |
| 18.04.2022 | Life Scien... | lspvc.com |
Mentions in press and media 7
| Date | Title | Description |
| 07.09.2024 | Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting | April 04, 2024 03:30 PM Eastern Daylight Time Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting In the poster, entitled “EGL-001 is a novel immunocytokine... |
| 07.09.2024 | EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Indepen... | Paris, France, May [date], 2024 – EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appoin... |
| 10.04.2024 | EGLE announces $320,000 grant opportunity for community solar projects | The Energy Unit of the Michigan Department of Environment, Great Lakes, and Energy (EGLE) is offering grants to help address communities’ roadblocks to clean energy access. At least $320,000 in funding is expected to be available through th... |
| 25.10.2021 | Democrats look to Billionaire tax on unrealized capital gains | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. As Democrats seek ways to pay for a proposed roughly $2 trillion social spending bill, a new annu... |
| 22.10.2021 | Egle Therapeutics Raises €40M in Series A Funding | Egle Therapeutics, a Paris, France-based biotechnology company that focuses on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, completed a €40M ($46.4M) ... |
| 22.10.2021 | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers About Egle Therapeutics About LSP About Bpifrance – InnoBio 2 About Tak... | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has c... |
| - | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers | LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate |